Lucid Diagnostics Begins Receiving Medicare Reimbursement for EsoGuard® and Closes $15 Million Financing
PR Newswire•22/10/2026•16:21 ET
0
Key Highlights
- ➤Medicare pays EsoGuard at established CLFS rate of $1,938.01 per test
- ➤Lucid closes $15.0 million Series C Preferred Stock private placement
- ➤Series C converts into common stock at $0.3519 per share
- ➤Medicare claim payments address Notes’ Medicare-related event-of-default concerns
Expert Statements
Lishan Aklog, M.D., Chairman and Chief Executive Officer of Lucid Diagnostics
“Medicare is now paying for EsoGuard”
Lucid Diagnostics Begins Receiving Medicare Reimbursement for EsoGuard® and Closes $15 Million Financing PR Newswire
Lucid is now submitting Medicare claims and receiving payments at EsoGuard's established Clinical Laboratory Fee Schedule rate
Get started
Create a free account to read the full story.